Regorafenib is approved by US-FDA for the treatment of HCC (2017), CRC (2012), and gastrointestinal stromal tumor (2013).43 Our previous study confirmed that regorafenib treatment upregulated PSAT1 by directly binding with it and prevented its proteasome-mediated degradation in glioblastoma.24 Since upregulated PSAT1 may lead to enhanced mitochondrial function and tumor metastasis in the tumor-possessed p5372P variant, we inferred that the addiction of tumors possessing the p5372P variant to PSAT1 made them more susceptible to PSAT1 inhibitors such as AOA. Here, PSAT1 is linked to gastrointestinal stromal tumor.